intismeran autogene

all catalysts(0)

nothing on the calendar yet

News(10)

• BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
  BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
  biospace · 2h ago
• Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
  Eric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…
  fiercebiotech · 1d ago
• Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
  Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
  biospace · 8d ago
• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 18d ago
• After a brief storm of political headwinds, mRNA is back with strong momentum
  A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved Moderna’s flu vaccine based on the technology. Weeks later, Moderna and M…
  biospace · 18d ago
• mRNA cancer vaccines’ biggest barriers to market
  Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
  biopharma_dive · 21d ago
• Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
  Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
  biospace · 24d ago
• Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
  After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.
  biospace · 24d ago
• Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
  The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient survival in a phase 3 study affirmed the two companies' years of hard wor…
  fiercebiotech · 1mo ago
• BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
  Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…
  biospace · 1mo ago